SOUTHBOROUGH, Mass.–( BUSINESS WIRE )– Veristat , the full-service and consulting “science first” CRO, announced the appointment of Rachel Page to its leadership team . Ms. Page, who joins Veristat as Chief Commercial Officer, succeeds longtime Veristat executive Cindy Henderson, who recently became Chief Strategy Officer and will focus on developing and implementing the company’s strategy focused on the Veristat customer.
With over 20 years of experience in global health and science commercialization, Rachel Page has all the skills needed to energize our brand and leverage our deep industry expertise. His expertise will be crucial in helping biopharmaceutical companies address their most complex clinical and regulatory challenges to accelerate the delivery of innovative therapies.
“Veristat has a 30-year track record of implementing innovative methods that help bring often life-changing therapies to patients who need them,” said Patrick Flanagan, CEO. “Rachel Page’s accomplishments and experience in empowering people, building business organizations, and fostering trusted client relationships demonstrate her ability to successfully lead the execution of our strategic plan. Ms. Page’s unwavering commitment to her clients’ success has received tremendous recognition. I am confident in its ability to leverage Veristat’s extensive global industrial experience. »
Rachel Page’s extensive global network and extremely successful track record across all stages of the pharmaceutical lifecycle will be instrumental in achieving dramatic results for our clients.
“I am thrilled to join this dynamic, science-driven team,” said Rachel Page. “Veristat is an exceptional partner when it comes to facilitating the delivery of critical therapies and transforming customer businesses. I am honored to collaborate with such a passionate group of leaders, colleagues and customers who are dedicated to accelerating the delivery of breakthrough treatments to patients with complex diseases. I look forward to leading our talented global sales team and helping achieve our customers’ vital goals. »
In her new role, Rachel Page will oversee Veristat’s go-to-market strategy and operations, including business development, proposals, contracts, marketing and fostering strong customer relationships. She will also focus on the growth and development of the sales team, to continually ensure the needs of our customers are met.
About Veristat
Veristat is the “Science-First CRO™ and Consultancy” company that provides comprehensive clinical trial execution, regulatory and safety affairs, and strategic consulting services to rapidly advance development, approval and marketing of innovative therapies (#NovelTherapies) worldwide. With 30 years of experience solving sponsors’ specific and complex clinical, statistical and regulatory challenges, Veristat’s science-first experts quickly deliver quality-driven results and solutions tailored to patient needs. , clinical trial sites, regulators, sponsor teams and key stakeholders.
Veristat’s focus on developing new drugs has led to success when it comes to treating any unknown event, from the simplest to the most complex, that can arise in many therapeutic areas, including rare/ultra -rare, innovative therapies, oncology and biological products, including cell and gene therapies (#cellandgenetherapy), to enable sponsors to succeed and prolong and save patients’ lives. Sponsors collaborate with Veristat’s dedicated science-first experts. For Veristat, it’s not about doing business, it’s about serving people.
